Merck and Serum Institute Announce Collaboration

MerckMerck (NYSE: MRK), known outside the United States and Canada as MSD, and Serum Institute of India Limited, an Indian company, announced an agreement to work together to develop and commercialize a pneumococcal conjugate vaccine (PCV) for use in the emerging and developing world countries. It is estimated that one out of every two children immunized in the world is vaccinated by a vaccine manufactured by Serum Institute. In addition, Merck has developed more than one-third of the world's vaccines for children, adolescents and adults.

"Serum Institute is committed to improving access to and affordability of vaccines for children throughout the world," said Cyrus Poonawalla, CMD, Chairman, Serum Institute, "In working closely with Merck in the development of this collaboration it became clear that we share parallel public health goals and that our passion for getting vaccines to everyone who needs them is made even stronger by working together."

Pneumococcal disease is a bacterial infection that causes pneumonia, meningitis, sepsis and other life-threatening ailments. Current estimates show that at least one million children die of pneumococcal disease every year, including mostly young children in developing countries.

"Working side by side with Serum gives us the best chance of developing and bringing a product to the market that will help to protect more babies and children," said Julie L. Gerberding, president, Merck Vaccines. "Expanding vaccine access to emerging and developing markets is a top priority and we feel strongly that this collaboration will be a giant step toward impacting the devastation of pneumococcal disease."

Together, Merck and Serum will form a Product Advisory Committee to oversee the activities required to develop and seek approval for PCV and pursue World Health Organization (WHO) prequalification. Under the terms of the agreement, Merck, through an affiliate, will receive specific rights to market PCV in certain designated territories and Serum will receive specific rights in other territories. Both companies will contribute to the development and manufacture of PCV. Specific financial details of this agreement are confidential. This collaboration does not impact the on-going vaccine development programs in both the organizations.

About Merck
Today's Merck is a global healthcare leader working to help the world be well. Merck is known as MSD outside the United States and Canada. Through our prescription medicines, vaccines, biologic therapies, and consumer care and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to healthcare through far-reaching policies, programs and partnerships.

About Serum Institute
Serum Institute of India based in Pune/India today is the largest manufacturer of DTP and MMR Group of Vaccines and supplying its products to U.N. Agencies as also to more than 140 countries. The recent launch of MenAfriVacTM which was especially developed for Sub-Saharan Africa has been acknowledged by one and all related to the vaccine community. It is a policy and commitment of Serum Institute of India to make the new vaccines available at affordable prices to the children of developing world.

Most Popular Now

Regorafenib to be tested in brain cancer patients …

Bayer announced that the regorafenib arm of the platform trial "GBM AGILE" (Glioblastoma Adaptive Global Innovative Learning Environment) opened for enrollment in the US ...

Sanofi and Google to develop new healthcare Innova…

Sanofi and Google will establish a new virtual Innovation Lab with the ambition to radically transform how future medicines and health services are delivered by tapping i...

Bristol-Myers Squibb provides update on pending me…

Bristol-Myers Squibb Company (NYSE: BMY) today provided an update on the approval process and timeline for the Company’s pending merger with Celgene Corporation (NASDAQ: ...

Artificial DNA can control release of active ingre…

A drug with three active ingredients that are released in sequence at specific times: Thanks to the work of a team at the Technical University of Munich (TUM), what was o...

LEO Pharma completes the acquisition of Bayer’s pr…

LEO Pharma and Bayer announced today the achievement of the relevant closing conditions to allow the transfer of Bayer’s global prescription dermatology business to LEO P...

Pathogen engineered to self-destruct underlies can…

A team of investigators has developed a cancer vaccine technology using live, attenuated pathogens as vectors. A feature of the vaccine causes these bacteria to self-dest...

Novartis successfully completes acquisition of Xii…

Novartis today announced that it has completed its acquisition of Xiidra® (lifitegrast ophthalmic solution) 5%, the first and only prescription treatment approved to trea...

How gastric stem cells fight bacteria

Stem cells are not only key players in tissue regeneration, they are also capable of taking direct action against bacteria. This is the finding of a study conducted by re...

New study showing drug prolongs life for patients …

Women with ovarian cancer who have undergone four or more rounds of chemotherapy typically haven't had much hope that another treatment option will lengthen their lives i...

Pfizer completes acquisition of Therachon

Pfizer Inc. (NYSE: PFE) announced the successful completion of its acquisition of the privately held clinical-stage biotechnology company Therachon Holding AG. Under the ...

Sports playbook helps doctors predict cancer patie…

In this season of global soccer competitions and hotly contested political primaries, bookies and pundits are scouring every evolving scrap of information and sifting thr...

FDA seeks public feedback on new drug approval tra…

Today the U.S. Food and Drug Administration issued a Federal Register notice, New Drugs Regulatory Program Modernization: Improving Approval Package Documentation, to ope...